Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial

PHASE3RecruitingINTERVENTIONAL
Enrollment

826

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

December 30, 2025

Study Completion Date

December 31, 2025

Conditions
Surgical Site InfectionDementiaCognition
Interventions
DRUG

Tranexamic Acid 100Mg/ml Inj Vial 10ml

Intervention is from the Tranexamic acid to Reduce Infection after Gastrointestinal Surgery: the TRIGS Trial. A multicentre, pragmatic, double-blind, randomised clinical trial will compare the incidence of surgical site infection and red cell transfusion requirements after IV tranexamic acid and placebo in patients undergoing gastrointestinal surgery

DRUG

Placebo

Normal saline

Trial Locations (2)

3181

RECRUITING

Alfred Health, Melbourne

RECRUITING

Alfred Health, Melbourne

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Monash University

OTHER

lead

Bayside Health

OTHER_GOV

NCT05470816 - Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial | Biotech Hunter | Biotech Hunter